New Pill-and-Infusion combo aims to keep liver cancer in check
Disease control
Not yet recruiting
This phase 2 study tests whether adding the experimental drug zanzalintinib to the approved immunotherapy durvalumab can help people with advanced liver cancer live longer. Participants have already responded to an initial treatment of tremelimumab plus durvalumab and are now on …
Phase: PHASE2 • Sponsor: Amit Mahipal • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC